Treatment Options for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

home / insights / treatment-options-for-relapsed-refractory-diffuse-large-b-cell-lymphoma
Therapy Initiation Prior to Cytogenetic Testing Results

EP. 1: Therapy Initiation Prior to Cytogenetic Testing Results

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
DLBCL Risk Assessment and Genetic Signatures

EP. 2: DLBCL Risk Assessment and Genetic Signatures

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
Newly Diagnosed DLBCL: Treatment Decision Factors

EP. 3: Newly Diagnosed DLBCL: Treatment Decision Factors

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
R/R DLBCL: Transplant Eligibility and R-CHOP

EP. 4: R/R DLBCL: Transplant Eligibility and R-CHOP

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
Relapsed/Refractory DLBCL Treatment Landscape

EP. 5: Relapsed/Refractory DLBCL Treatment Landscape

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
CAR T Cell Therapy in Relapsed/Refractory DLBCL

EP. 6: CAR T Cell Therapy in Relapsed/Refractory DLBCL

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
CAR T-Cell Therapy Response Rates

EP. 7: CAR T-Cell Therapy Response Rates

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
CAR T-Cell Therapy Clinical Trials

EP. 8: CAR T-Cell Therapy Clinical Trials

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
SADAL Trial Overview

EP. 9: SADAL Trial Overview

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
SADAL Trial Regimen FDA Approval

EP. 10: SADAL Trial Regimen FDA Approval

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
Emerging Treatments for Relapsed/Refractory DLBCL

EP. 11: Emerging Treatments for Relapsed/Refractory DLBCL

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
Relapsed/Refractory DLBCL: Unmet Needs

EP. 12: Relapsed/Refractory DLBCL: Unmet Needs

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
Novel Treatment Combinations for R/R DLBCL

EP. 13: Novel Treatment Combinations for R/R DLBCL

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020
Novel Therapies: R2-GDP-GOTEL and Smart Start

EP. 14: Novel Therapies: R2-GDP-GOTEL and Smart Start

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020